Dermapharm Holding SE (ETR:DMP)
36.65
-0.70 (-1.87%)
Mar 31, 2025, 2:39 PM CET
Dermapharm Holding SE Revenue
Dermapharm Holding SE had revenue of 314.56M EUR in the quarter ending September 30, 2024, with 9.48% growth. This brings the company's revenue in the last twelve months to 1.17B, up 0.17% year-over-year. In the year 2023, Dermapharm Holding SE had annual revenue of 1.15B with 10.59% growth.
Revenue (ttm)
1.17B
Revenue Growth
+0.17%
P/S Ratio
1.72
Revenue / Employee
335.70K
Employees
3,497
Market Cap
2.01B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.15B | 110.19M | 10.59% |
Dec 31, 2022 | 1.04B | 80.46M | 8.38% |
Dec 31, 2021 | 960.09M | 151.78M | 18.78% |
Dec 31, 2020 | 808.31M | 93.94M | 13.15% |
Dec 31, 2019 | 714.38M | 130.28M | 22.30% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Merck KGaA | 21.16B |
Siemens Healthineers AG | 22.67B |
Fresenius SE & Co. KGaA | 21.83B |
Bayer Aktiengesellschaft | 46.61B |
Sartorius Aktiengesellschaft | 3.38B |
Fresenius Medical Care AG | 19.34B |
Carl Zeiss Meditec AG | 2.08B |
Fielmann Group AG | 2.16B |
Dermapharm Holding SE News
- 3 days ago - Dermapharm's 2024: Revenue Soars, Surpassing EBITDA Expectations - Wallstreet:Online
- 3 days ago - EQS-News: Successful financial year 2024: Dermapharm increases revenue and exceeds EBITDA guidance - Wallstreet:Online
- 13 days ago - EQS-DD: Dermapharm Holding SE: Themis Beteiligungs-Aktiengesellschaft, buy - Wallstreet:Online
- 17 days ago - Dermapharm Surpasses EBITDA Forecast with Revenue Boost - Wallstreet:Online
- 17 days ago - EQS-News: Dermapharm Holding SE increases revenue as projected and exceeds guidance for adjusted consolidated EBITDA - Wallstreet:Online
- 3 months ago - EQS-DD: Dermapharm Holding SE: Wilhelm Beier, buy - Wallstreet:Online
- 4 months ago - EQS-DD: Dermapharm Holding SE: Dr. Hans-Georg Feldmeier, buy - Wallstreet:Online
- 5 months ago - EQS-DD: Dermapharm Holding SE: Christof Dreibholz, buy - Wallstreet:Online